Harvard Clinical and Translational Science Center

哈佛临床和转化科学中心

• 批准号: 8721090
• 负责人: Lee Marshall Nadler
• 金额: $ 60.52万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8721090
• 关键词: Achievement; Address; Biological Markers; Center for Translational Science Activities; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Commit; Communities; Coupled; Education; Environment; Future; Goals; Health; Healthcare; Home environment; Human; Human Experimentation; Incentives; Institution; Instruction; Investigation; Methodology; Participant; Pathway interactions; Patients; Prevention; Research Infrastructure; Research Personnel; Research Training; Resolution; Resources; Safety; Schools; Science; Services; Speed; Strategic Planning; Structure; Therapeutic; Training; Training and Education; Transcend; Translating; Translational Research; Vision; Work; career development; catalyst; cost; improved; innovation; medical schools

Harvard Catalyst has transcended the boundaries long imposed by the historical, corporate, and cultural independence of Harvard and its 17 affiliated academic healthcare centers (AHCs) to bring cross-disciplinary investigators together to collaborate and form teams to conduct clinical and translational (CT) research. Today education, resources and services are jointly planned, executed, broadly shared, and evaluated with the common goal of improving the quality, speed, safety, efficiency and cost across the entire spectrum of CT research. Ongoing CTSA recognition coupled with the opportunity to be a significant participant in the Consortium will enable Harvard Catalyst to implement its vision and strategic plan. First, we will convene investigators from our 11 schools and 17 AHCs to identify and prioritize the most important opportunities in CT research. We will help them to connect with one another to form cross-disciplinary teams and then provide them with the opportunities, incentives, and access to outstanding education and resources in an environment that values innovation, collaboration, and team science. Second, we will work with our schools and AHCs to build and grow an environment where discoveries are rapidly and efficiently translated to improve human health. Simply stated, Harvard Catalyst strives to be a Convener, Connector and Catalyst to hasten and improve the quality CT research. To this end, we have structured our academic home to create an integrated pathway of education, training, and career development and to provide a full portfolio of innovative resources and services to address identified gaps and investigator needs. Within five years, our achievements will include: 1) a continuous, sustainable, robust pipeline of future team leaders across all CT domains; 2) implementation of SHRINE-CT coupled with resolution of regulatory hurdles to allow investigators to rapidly identify, contact, and accrue specific patients to clinical trials across institutions and throughout the Consortium; 3) establishment of a team of experts who will reduce the barriers to engagement and entry to human experimentation thereby growing and diversifying the community of investigators who conduct CT research; 4) infrastructure to provide all CT investigators access to the resources they need to conduct human clinical studies wherever their work is best done; and 5) systematic investigation of innovative methodologies to incentivize, form and nurture teams to create new preventions, biomarkers, and therapeutics. These achievements will continue the transformation of CT research at Harvard with the goal of catalyzing a "One Harvard" community and culture committed to improving health. RELEVANCE (See instructions): The Harvard Clinical and Translational Science Center supports an academic home that creates an integrated research and training environment across Harvard Medical School and its partner institutions in order to improve human health. It provides and/or creates access to resources and services to support all steps of clinical research across the full spectrum of clinical and translational research, and facilitates the training and career development of the translational research workforce.

哈佛催化剂超越了历史、企业和文化长期强加的界限 哈佛大学及其 17 个附属学术医疗中心 (AHC) 的独立性带来了跨学科 研究人员共同协作并组建团队来进行临床和转化（CT）研究。 如今，教育、资源和服务是与以下机构共同规划、执行、广泛共享和评估的： 提高整个领域的质量、速度、安全性、效率和成本的共同目标 CT研究。持续获得 CTSA 认可以及成为重要参与者的机会 联盟将使Harvard Catalyst能够实施其愿景和战略计划。首先，我们将召开 来自我们 11 所学校和 17 个 AHC 的调查员确定并优先考虑最重要的机会 CT研究。我们会帮助他们互相联系，组成跨学科的团队，然后 为他们提供机会、激励以及获得优质教育和资源的机会 重视创新、协作和团队科学的环境。第二，我们将与我们的学校合作 和 AHC 建立和发展一个环境，使发现能够快速有效地转化为 改善人类健康。简而言之，Harvard Catalyst 致力于成为召集者、联络者和催化剂 加快和提高CT研究质量。为此，我们构建了我们的学术家园 创建教育、培训和职业发展的综合途径，并提供完整的投资组合 创新资源和服务，以解决已发现的差距和研究者的需求。五年内，我们的 成就将包括：1）在所有 CT 领域建立持续、可持续、强大的未来团队领导者队伍 域； 2) 实施 SHRINE-CT 并解决监管障碍，以允许 研究人员可以快速识别、联系和吸引特定患者参加跨机构和临床试验 整个联盟； 3）建立专家团队，减少障碍 参与和进入人体实验，从而使社区发展和多样化 进行 CT 研究的研究者； 4) 为所有 CT 调查员提供访问的基础设施 他们在最适合开展工作的地方进行人体临床研究所需的资源； 5）系统性 研究创新方法，以激励、组建和培养团队，以创造新的预防措施， 生物标志物和治疗方法。这些成果将继续推动CT研究的变革 哈佛的目标是促进“一个哈佛”社区和文化，致力于改善健康。 相关性（参见说明）： 哈佛临床和转化科学中心支持一个学术之家，该中心创建了一个 哈佛医学院及其合作机构的综合研究和培训环境 以改善人类健康。它提供和/或创建对资源和服务的访问以支持所有 整个临床和转化研究领域的临床研究步骤，并促进 转化研究人员的培训和职业发展。